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ABSTRACT A20 is a NF-B-dependent gene that has
dual anti-inflammatory and antiapoptotic functions in
endothelial cells (EC). The function of A20 in smooth
muscle cells (SMC) is unknown. We demonstrate that
A20 is induced in SMC in response to inflammatory
stimuli and serves an anti-inflammatory function via
blockade of NF-B and NF-B-dependent proteins
ICAM-1 and MCP-1. A20 inhibits SMC proliferation via
increased expression of cyclin-dependent kinase inhib-
itors p21waf1 and p27kip1. Surprisingly, A20 sensitizes
SMC to cytokine- and Fas-mediated apoptosis through a
novel NO-dependent mechanism. In vivo, adenoviral
delivery of A20 to medial rat carotid artery SMC after
balloon angioplasty prevents neointimal hyperplasia by
blocking SMC proliferation and accelerating re-endo-
thelialization, without causing apoptosis. However, ex-
pression of A20 in established neointimal lesions leads
to their regression through increased apoptosis. This is
the first demonstration that A20 exerts two levels of
control of vascular remodeling and healing. A20 pre-
vents neointimal hyperplasia through combined anti-
inflammatory and antiproliferative functions in medial
SMC. If SMC evade this first barrier and neointima is
formed, A20 has a therapeutic potential by uniquely
sensitizing neointimal SMC to apoptosis. A20-based
therapies hold promise for the prevention and treat-
ment of neointimal disease.—Patel, V. I., Daniel, S.,
Longo, C. R., Shrikhande, G. V., Scali, S. T., Czismadia,
E., Groft, C. M., Shukri, T., Motley-Dore, C., Ramsey,
H. E., Fisher, M. D., Grey, S. T., Arvelo, M. B., Ferran,
C. A20, a modulator of smooth muscle cell prolifera-
tion and apoptosis, prevents and induces regression of
neointimal hyperplasia. FASEB J. 20, 1418–1430 (2006)
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Proliferation of smc, their acquisition of a synthetic,
proinflammatory phenotype, as well as their recently
recognized “high” resistance to apoptosis are central
events in the pathogenesis of vascular lesions, including
vein graft occlusion, postangioplasty restenosis and
transplant arteriosclerosis (TA), an accelerated form of
atherosclerosis (1–3). Restenosis occurs in 20% to 40%
of patients within the first few months after successful
angioplasty and is only delayed with stent implantation
(4). Stent failure remains unacceptably high with reste-
nosis incidence reaching 30% (4).
Novel therapies aimed at blocking SMC proliferation
such as rapamycin/sirolimus-coated stents demonstrate
promising clinical potential (5). However, this benefit
is still insufficient particularly in diabetic patients,
prompting the exploration of additional therapeutic
leads (6). With the recent appreciation that atheroscle-
rosis and restenosis may reflect failure in apoptotic
pathways mediating regression of neointima, several
proapoptotic strategies have been successfully explored
in experimental models of neointimal disease includ-
ing down-regulation of the antiapoptotic bcl family
member Bcl-xL, inhibition of Survivin, a member of the
inhibitors of apoptosis proteins family, overexpression
of Fas ligand or increasing NO levels, a known apopto-
tic stimulus to SMC (7–11).
We hypothesize that a strategy combining anti-in-
flammatory/antiproliferative and proapoptotic effects
in SMC could be optimal to prevent/treat neointimal
vascular disease. We had previously shown that the zinc
finger protein A20 is part of the endothelial cell (EC)
response to injury. In EC, A20 serves a broad anti-
inflammatory function via inhibition of the transcrip-
tion factor NF-B and an antiapoptotic function
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through inhibition of the initiator caspase 8, both
beneficial to contain vascular disease (12–16). NF-B is
also a critical effector of the SMC response to injury
and is required for SMC activation and proliferation in
vitro and for progression of atherosclerotic plaques in
vivo (17). We reasoned that if A20 inhibits NF-B
activation in SMC, as it does in EC, its overexpression
could positively affect vascular remodeling after injury
by inhibiting SMC activation and proliferation. How-
ever, if A20 was to maintain its antiapoptotic function in
SMC, its expression could increase SMC resistance to
apoptosis and contribute to neointima formation. Indi-
rect evidence from rat renal kidney allografts demon-
strating a strict inverse correlation between the expres-
sion of A20 in SMC and the incidence of TA rather
favored the “atheroprotective” potential of A20 in SMC
(18).
In this study, we explore the function(s) of A20 in
SMC and evaluate its effect on NF-B activation, cell
proliferation and apoptosis in vitro and its effect on
development and progression/regression of neointi-
mal disease, in vivo, using a rat model of neointimal
hyperplasia after balloon angioplasty to carotid arteries
(19).
MATERIALS AND METHODS
Reagents
Porcine aortic endothelial cells (PAEC) were cultured as
described (13). We purchased human aortic (HASMC) and
human coronary artery (HCSMC) SMC from Cambrex (Walk-
ersville, MD, USA), 293 kidney embryonic cell line from
American Type Culture Collection (Rockville, MD, USA),
human recombinant TNF, IL-1 and IFN from R&D Systems
(Minneapolis, MN, USA), anti-Fas IgM antibody (Ab) (clone
CH-11, Fas) from Kamiya Biomedical Company (Seattle,
WA, USA), the control mouse IgM from Accurate Chemical &
Scientific Corporation (Westbury, NY, USA) and the NO
synthase inhibitor l-NAME from Sigma (St. Louis, MO, USA).
Recombinant adenoviral vectors
We generated recombinant adenoviral vectors encoding A20
(rAd.A20), A1 (rAd.A1), IB (rAd.IB), and A20 silencing
RNA (rAd.SiRA20) using the siRNA sequence previously
described (20) and expanded them in 293 cells (13). Control
rAd.-galactosidase was a kind gift from Dr. R. Gerard (Uni-
versity of Texas SW, Dallas). The A20 expression plasmid used
to generate rAd.A20 was a kind gift from Dr. V. Dixit
(Genentech Inc., S. San Francisco, CA, USA). We infected
SMC with rAd.A20, rAd.IB, and rAd.-gal at a multiplicity
of infection (MOI) of 500, resulting in 95–100% of cells
expressing the transgene without toxicity.
Western blot analysis (WB)
We used the following antibodies (Abs): rabbit anti-IB IgG
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), mouse
anti-CDKI p21waf1 IgG1, mouse anti-CDKI p27
kip1 IgG1,
mouse antip53 IgG2b, mouse anti-Rb IgG1 (PharMingen, San
Diego, CA, USA), rat anti-hemagglutinin IgG1 monoclonal
antibody (Roche Molecular Biochemicals, Indianapolis, IN,
USA), mouse anti--tubulin IgG2b (Chemicon International,
Inc., Temecula, CA, USA), and rabbit anti-A20 polyserum
generated in our lab. Secondary antibodies included peroxy-
dase-conjugated donkey anti-rabbit IgG (HL), goat anti-
mouse IgG and goat antirat IgG (Pierce, Rockford, IL, USA).
Electrophoretic mobility shift assay (EMSA)
We extracted nuclear proteins and analyzed them by EMSA as
described (13).
Flow cytometric analysis of ICAM-1 expression
We analyzed for ICAM-1 surface expression by flow cytometry
(FACScan, Becton Dickinson, Immunocytometry systems, San
Jose, CA, USA) using a mouse anti-human ICAM-1 IgG (R&D
Systems, Minneapolis, MN, USA). An isotype IgG1 was used as
a control (13).
Northern blot analysis
We extracted RNA using Trizol reagent (Gibco BRL, Grand
Island, NY, USA). Human A20, MCP-1, and GAPDH cDNA
were previously described (13).
Flow cytometric analysis of apoptosis
SMC apoptosis was induced by treatment with TNF, IFN, and
interleukin (IL)-1 for 48 h, then DNA content was analyzed
on a FACScan using CELLQuest software (Becton Dickson
Immunocytometric Systems, San Jose, CA, USA) as described
(14).
Cell cycle analysis
Cell cycle was synchronized by culturing SMC in 0.1% FBS
SmBM® for 48 h and gene transduction was conducted using
rAd.A20, rAd.IB, and rAd.-gal. We challenged SMC 24 h
later with 10% FBS SmBM® and analyzed cell cycle by FACS
analysis of DNA content. DNA ploidy allows discrimination of
cells in G0/G1, S, and G2/M phases of the cell cycle. In certain
experiments, 5 mM of l-NAME (Sigma) was added 6 h prior
to challenging SMC with 10%FBS.
Balloon angioplasty
We performed balloon injury on adult male SD rats (300–400
g) from Harlan (Indianapolis, IN, USA) as described (19).
Using a 2F embolectomy catheter (Baxter Edwards Health-
care, Irvine, CA, USA), we injured 1 to 1.5 cm of the left
common carotid artery by intraluminal balloon inflation and
passage 3 times. In the prevention studies, the injured vessel
segment was filled with 30 l of vehicle or 5.108 MOI of
rAd.A20 or rAd.-gal for 20 min. We sacrificed the animals 14
and 28 days later and injured carotids were recovered, fixed
in 10% formalin and embedded in paraffin. Additional
injured carotids were recovered at 3 and 7 days and frozen for
immunohistochemistry analysis. In the regression model, the
injury site was re-explored 28 days later and proximal and
distal control were obtained with clamps and the vessel filled
with 30 l of vehicle or rAd. using a 30G needle. Following a
20 min dwell, we flushed the lumen and closed the needle
hole before allowing recirculation. We sacrificed the rats at
days 28  1, 28  3, 28  5, 28  7, and 28  14 and vessels
were recovered for morphometry and immunohistochemistry
analysis. Animals were housed in the BIDMC animal care
facility. All procedures and protocols were approved and
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performed in accordance with the BIDMC institutional ani-
mal care committee and published NIH guidelines.
Histology and immunohistochemistry
For morphometric analysis, we sectioned and stained paraffin
embedded tissues with hematoxylin/eosin (H&E) and mea-
sured intima /media (I/M) ratio using the NIH Image 1.62
software in a blinded fashion. Six to eight rats were used per
time point and per group and six to ten serial sections, 50 m
apart, were measured for each vessel. For immunohistochem-
istry analysis, frozen sections were stained with mouse anti-
human Ki-67 IgG1 (PharMingen), mouse antirat CD31 IgG1,
rabbit antimouse and rat inducible nitric oxide synthase
(iNOS) (iNOS; M-19, Santa Cruz Biotech., Santa Cruz, CA,
USA) followed by biotinylated horse antimouse-IgG or goat
anti-rabbit secondary antibodies (Vector, Burlingame, CA,
USA). We detected apoptosis using a tissue-specific TUNEL
kit: VASOTACS (Trevigen Inc., Gaithersburg, MD, USA).
Sections were scored for percentage of luminal staining for
CD31 and for the number of KI67 or TUNEL positive cells
per section while a semiquantitative scoring for iNOS expres-
sion in SMC was done: 0 absence of staining, 1 faint staining,
2 intense staining. Blinded observers evaluated two or more
sections from 3 to 4 individual animals per time point and per
group. Beta-galactosidase expression in injured vessels was
detected using X-gal (Sigma, St. Louis, MO, USA).
RT-polymerase chain reaction and real-time-polymerase
chain reaction
We extracted RNA from vessels or Kits using RNeasy Mini Kits
(Qiagen, Valencia, CA, USA) and synthesized cDNA using
Superscript First-Strand Synthesis (Invitrogen, Carlsbad, CA,
USA). polymerase chain reaction (PCR) reactions were per-
formed with the following primers: rat -actin: sense, 5-
TCATGAAGTGTGACGTTGACATCCGT-3, and antisense,
5- CTTAGAAGCATTTGCGGTGCACGATG-3; human A20:
sense, 5TTTGAGCAATATGCGGAAAGC-3, and antisense,
5-AGTTGTCCCATTCGTCATTCC-3; human iNOS: sense:
5-GGCCTCGCTCTGGAAAGA-3, and antisense 5-TCCATG-
CAGACAACCTT-3. RNA was also extracted from HASMC to
check for human A1 mRNA levels using previously described
primers (21). PCR reactions were optimized for each primer
pair. We performed PCR over a range of cycles (15–40) to
ensure amplification in the linear range and used equal
starting amounts from each sample. In addition, real-time
(quantitative) PCR reactions were performed using primers
from Applied Biosystems assays-on-demand to quantify hu-
man iNOS mRNA. Amplification of ribosomal 18s was used to
correct for loading.
Statistical analysis
Quantitative data was expressed as mean 	se. If SD were
equal within the populations, an unpaired 2-tailed Student’s t
test was used to compare treatment groups. If sd values
differed significantly, a nonparametric Mann-Whitney test was
used. A value of P 
 0.05 was considered statistically signifi-
cant.
RESULTS
A20 inhibits NF-B activation in SMC upstream
of IB degradation
We induced A20 mRNA (Northern blot) and protein
(WB) expression in SMC 1 h and 6 h after stimulation
with 100U/ml of tumor necrosis factor  (TNF), re-
spectively (Fig. 1A). This result demonstrates that A20 is
part of the physiological response of SMC to inflamma-
tion. We next tested whether A20 manifests its NF-B
inhibitory function in SMC. We stimulated SMC with
100 U/ml of TNF and nuclear and cytoplasmic extracts
were recovered from nontransduced (NT), (rAd.)
rAd.A20, and rAd.-gal -transduced SMC at 0, 15, and
120 min. Overexpression of A20 in SMC inhibited IB
degradation (WB) after TNF stimulation (Fig. 1B).
SMC transduced with rAd.SiRA20 demonstrated lasting
IB degradation (120 min) indicating, as in knock-out
Figure 1. Northern blot analysis and Western blot analysis of
A20 mRNA and protein after treatment with TNF (A).
Overexpression of A20 in SMC inhibits IB degradation
after TNF stimulation as shown by Western blot analysis,
whereas knockdown of A20 SiRNA leads to prolonged IB
degradation (B). Similarly, A20 expression in SMC inhibits
NF-B nuclear translocation 2 h after TNF (TNFT). Specific
competitor (SC); nonspecific competitor (NSC); control (C)
are nuclear extracts recovered prior to addition of TNF (C).
A20 expression in SMC inhibits TNF-mediated ICAM-1 up-
regulation (FACS analysis; empty histogram). Nontreated
SMC control (filled histogram) (D) and TNF-mediated
MCP-1 up-regulation (Northern blot analysis) (E). Results
shown are representative of 3 independent experiments.
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A20 mice, prolonged NF-B activation (22)(Fig. 1B).
We also showed by EMSA that there was no TNF
inducible binding for the NF-B consensus oligonucle-
otides in A20-expressing SMC as opposed to high
binding in NT or rAd.-gal-transduced SMC (Fig. 1C).
As a corollary, A20 expression in SMC inhibited TNF-
mediated up-regulation of the proinflammatory/
proatherogenic NF-B-dependent genes ICAM-1 and
MCP-1 as demonstrated by FACS and Northern blot
analysis, respectively (Fig. 1D, E).
Overexpression of A20 inhibits SMC proliferation
through blockade of Rb hyperphosphorylation
and an increased expression of CDKI p27kip1,
p21waf1, and p53
Having established that A20 inhibits NF-B activation,
we questioned whether such inhibition would affect
SMC proliferation. We synchronized the cell cycle of
SMC by culturing them in medium containing 0.1%
FBS, induced proliferation by adding 10% FBS, and
analyzed DNA content 24, 48, and 72 h later. We
showed no progression through the cell cycle in A20-
expressing SMC. The percentage of SMC in the
SG2/M phases of the cell cycle before and after
addition of FBS was comparable reaching 12 	 1% and
16 	 2%, respectively (n4; Fig. 2A). Overexpression
of IB, used as a positive control for NF-B inhibition,
equally prevented cell cycle progression (Fig. 2A),
suggesting that A20-mediated inhibition of SMC prolif-
eration could be related to its inhibition of NF-B. A20-
and IB-mediated inhibition of cell cycle progression
was maintained up to 72 h (data not shown), confirm-
ing that this effect was not merely a delay to entry. In
contrast, NT and rAd.-gal transduced SMC progressed
through the cell cycle after supplementation with FBS.
The percentage of NT and rAd.-gal transduced SMC
in the SG2/M phases of the cell cycle increased from
12 	 1% to 43 	 4% and 16 	 2% to 34 	 2%,
respectively, after 10% FBS (n4; Fig. 2A). SMC trans-
duced with rAd.-gal showed a delayed entry into cell
cycle (48 h) compared to NT SMC (24 h), which may
be attributable to adenoviral toxicity (Fig. 2A). To
dissect the molecular basis of A20-mediated inhibition
of cell cycling in SMC, we tested whether A20 expres-
sion modifies the phosphorylation of retinoblastoma
(Rb). Hyperphosphosphorylated Rb (ppRB) under-
goes a conformational change and releases E2F, a key
transcription factor involved in driving the cell cycle.
We showed that most of the Rb protein was in its
hypophosphorylated state at the end of the starvation
period (Fig. 2B). Hyperphosphorylated Rb was de-
tected 36 h after adding 10% FBS in NT and rAd.-gal
transduced SMC (Fig. 2B). Overexpression of either
A20 or IB in SMC inhibited Rb phosphorylation.
Sequential activation of cyclins D and E and their
cyclin-dependent kinases (CDK) drives phosphoryla-
tion of Rb during the G1 phase of the cell cycle. These
cyclin/CDK complexes are under the control of CDK
inhibitors (CDKI) (23). We evaluated whether A20
alters the expression of the CDKI p21waf1 and p27kip1.
Expression of p27kip1 was high at the end of SMC
starvation with a tendency to higher levels in rAd.-gal
transduced SMC. CDKI p27kip levels decreased substan-
tially 18 h after addition of FBS in NT and rAd.-gal
Figure 2. Cell cycle after addition of 10% FBS (FACS).
Overexpression of A20 and IB inhibits SMC progression
through the cell cycle. Histogram areas labeled A, B represent
cells in the G0/G1 and S  G2/M of the cell cycle (A).
Western blot of Rb demonstrates phosphorylation of RB
(ppRb) in NT (N) and rAd.-gal (B) transduced SMC but not
in rAd.A20 (A) and rAd.Ib (I) transduced SMC after
addition of 10% FBS (B). Expression of p27kip1, p21waf1, and
p53 is increased in A20- and IB-expressing SMC before and
18 h after addition of 10% FBS (Western blot analysis).
tubulin serves as a control for equal loading. Relative
protein expression is determined by densitometry and cor-
rected by the intensity of tubulin bands (C). Results shown
correspond to one representative experiment of 3 performed.
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transduced SMC. In contrast, p27kip1 protein levels
increased by 2- to 3-fold in rAd.IB and rAd.A20
transduced SMC (Fig. 2C). Protein levels of p21waf1
were low in NT SMC at the end of the starvation period
and increased very moderately 18 h after addition of
10% FBS. In contrast, high levels of p21waf1 were
detected in all rAd. transduced SMC at the end of
starvation, albeit these levels were twice as high in
rAd.IB and rAd.A20 transduced SMC compared to
those transduced with rAd.-gal. CDKIp21waf1 levels
further increased in A20- and IB-expressing SMC
18 h after addition of FBS, whereas they significantly
decreased in rAd.-gal transduced SMC (Fig. 2C).
Expression of p21waf1 is regulated in part by the tumor
suppressor gene p53 (24). We demonstrate that expres-
sion of p53 paralleled that of p21waf1 with sustained
up-regulation of p53 expression noted in A20- and
IB-expressing SMC before and after addition of 10%
FBS (Fig. 2C). The limited and moderate increase of
p53/p21waf1 and p27kip1 that was detected in rAd.-gal
transduced SMC prior to addition of FBS decreased
thereafter and likely accounts for their delayed entry in
the cell cycle. These data suggest that A20 blocks cell
cycle progression by increasing p53 and its target gene
p21waf1 as well as p27kip.
Overexpression of A20 sensitizes SMC to cytokine
and Fas-mediated apoptosis
A20 is an antiapoptotic protein in most cells including
EC but its effect on SMC apoptosis is not known. We
recovered NT, rAd.A20, rAd.IB, and rAd.-gal trans-
duced HASMC 48 h after treatment with 400 U/ml of
TNF, 400 U/ml of IFN and 100 U/ml of IL-1/ml and
evaluated apoptosis by DNA content analysis (14). The
percentage of apoptotic cells 48 h after cytokine treat-
ment was negligible in NT and rAd.-gal-transduced
SMC (
6%; Fig. 3A) while it increased significantly in
A20-expressing SMC from 4.0 	 0.5% to 36.6 	 4.2%
48 h after cytokine treatment (P
0.0001; n5). Despite
equivalent NF-B inhibition, SMC expressing IB
demonstrated less apoptosis than A20-expressing cells.
The percentage of apoptosis in IB-expressing SMC
increased from 3.0 	 1.0% to 13.0 	 3.0% (n5;
P0.001; Fig. 3A).
This unexpected proapoptotic effect of A20 in SMC
extends to the cross-linking of the death receptor Fas.
The percentage of apoptotic cells after treatment with
1 g/ml of Fas was negligible in NT and rAd.-gal-
transduced SMC (
2.2%; Fig. 3B) while a high rate of
apoptosis was detected in A20-expressing SMC, increas-
ing from 2.5 	 0.5% to 26.0 	 8.0% after addition of
Fas (n3; P
0.0001; Fig. 3B). Apoptosis was not
detected after treatment of SMC with the control IgM
Ab. Similar results were obtained in aortic or coronary
artery SMC. Both were used in later experiments and
referred to as SMC. These results demonstrate for the
first time a proapoptotic function for A20 in SMC.
A20-mediated sensitization of SMC to apoptosis is con-
sistently greater than that seen in IB-expressing
SMC, suggesting that this novel function of A20 is not
likely to be solely related to inhibition of NF-B.
Cotransduction of SMC with the antiapoptotic,
NF-B-dependent, bcl gene A1 does not revert the
proapoptotic effect of A20 while rescuing IB-
expressing SMC from apoptosis
To determine the molecular basis of the proapoptotic
effect of A20 in SMC, we questioned whether overex-
pression of A20 modified the ratio of antiapoptotic (A1,
Bcl-xL and IAP-1) and proapoptotic (Bcl-xS and Bax)
proteins in SMC. Messenger RNA levels for the anti-
Figure 3. SMC apoptosis was evaluated by DNA content
analysis after cytokine and Fas treatment. The hypodiploid
region (
2N), designated A0, represents cells undergoing
apoptosis. Overexpression of A20 in SMC sensitizes SMC to
cytokine (A) and Fas-mediated apoptosis. SMC stimulated
with IgM are used as controls (B). Data shown are from one
experiment that is representative of 5 (cytokines) and 3
(Fas) independent experiments.
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apoptotic bcl family member A1 were determined by
semiquantitative RT-PCR in NT and rAd.A20, rAd.IB
and rAd.-gal transduced SMC after addition of cyto-
kines. Low levels of A1 mRNA were detected prior to
adding cytokines and were up-regulated by 1.5- to
1.8-fold 3 h after in NT and rAd.-gal transduced SMC.
Expression of A20 and IB inhibited cytokine-medi-
ated up-regulation of A1mRNA (Fig. 4A), consistent
with studies showing that A1 is dependent on NF-B for its
induction (21). Comparable protein levels of Bcl-xL,
IAP-1, Bcl-xS and Bax were detected (WB) in all groups
before and after treatment with cytokines (data not shown).
To evaluate whether altered A1 induction was respon-
sible for increased SMC apoptosis in A20- and IB-
expressing SMC, NT SMC and SMC expressing A20, IB
and -gal were cotransduced with rAd.A1 prior to trigger-
ing apoptosis. SMC expressing A1 alone or in combina-
tion with -gal demonstrated low basal rate of apoptosis,
which was not modified by cytokine treatment (Fig. 4B).
SMC coexpressing A20 and A1 demonstrated higher basal
rate of apoptosis that was increased by cytokines, reaching
similar percentages to those reached in SMC expressing
A20 alone (34%, Fig. 4B, n3). In contrast, coexpression
of A1 and IB rescued SMC from cytokine-mediated
apoptosis (
4% apoptotic SMC after treatment with
cytokines; Fig. 4B). We confirmed coexpression of A1 and
A20 or A1 and IB by WB (Fig. 4B). These findings
provide additional proof that the proapoptotic function
of A20 in SMC is likely independent from its inhibitory
effect on NF-B and NF-B-dependent antiapoptotic pro-
teins such as A1.
The proapoptotic effect of A20 relates to NO-
dependent DNA fragmentation
We confirmed that cell death in SMC overexpressing
A20 was related to apoptosis and not necrosis by
showing a significant number of TUNEL positive apo-
ptotic nuclei in A20-expressing SMC after treatment
with cytokines (Fig. 5A) whereas none were detected in
rAd.-gal transduced SMC (data not shown). Despite
confirmation of apoptotic cell death, expression of A20
in SMC did not alter caspase 8 or 3 activity nor
disrupted the mitochondrial transmembrane potential
after cytokine treatment (data not shown), suggesting
that the proapoptotic effect of A20 in SMC was the
result of direct DNA damage. NO has been shown to
cause direct damage to DNA in SMC (25). We probed
for NO involvement in A20-mediated sensitization of
SMC to apoptosis. Pretreatment of rAd.A20 transduced
SMC with the NO synthase inhibitor l-NAME for 6 h
prior to adding cytokines led to a dose-dependent
reversal of the proapoptotic effect of A20 (Fig. 5B). The
rate of apoptosis increased from 4.5 	 0.8% to 16.0 	
1.3% (n4; P
0.0001) after addition of cytokines.
Preincubation of SMC with 2.5 mM and 5.0 mM of
l-NAME prior to adding cytokines decreased SMC
apoptosis to 9.4 	 0.9% (n4; P
0.0003) and 5.2 	
0.2% (n3; P
0.0001), respectively (Fig. 5B). These
results demonstrate that the novel proapoptotic func-
tion of A20 in SMC is NO dependent. Consequently,
induction of iNOS mRNA after stimulation with cyto-
kines was 2-fold higher in A20-expressing SMC com-
pared to controls (Fig. 5C). There was no or very little
iNOS mRNA detectable by real-time PCR prior to the
addition of cytokines. A significant increase in iNOS
mRNA was noted in A20-expressing SMC 18 h after
treatment with cytokines reaching a 4.07 	 0.8 (mRNA
Figure 4. Semiquantitative RT-PCR demonstrates increased
A1 mRNA levels NT and rAd.gal transduced SMC after
treatment with cytokines whereas no induction is detected in
A20- and IB-expressing SMC. Corrected densitometry al-
lowed determination of relative A1 mRNA levels (A). Cotrans-
duction of SMC with rAd.A1 reverts the proapoptotic effect of
IB but not that of A20 as determined by FACS analysis of
DNA content (B). Western blot analysis is done to check for
coexpression of the transgenes. Results shown are represen-
tative of 3 independent experiments.
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corrected with median computed tomography and 18s).
Cytokine-mediated increase of iNOS mRNA was signifi-
cantly lower in NT (1.47	0.41; P0.02) and rAd.gal
transduced SMC (1.86	0.26; P0.03; n2 experiments
performed in quadruplicate). High iNOS mRNA levels in
A20-expressing SMC persisted up to 36 h after addition of
cytokines (4	0.83). The molecular basis for increased
iNOS transcription in A20-expressing SMC after treat-
ment with cytokines is under investigation.
We then sought to clarify the potential implication of
NO in the anti-inflammatory and antiproliferative func-
tions of A20 in SMC. Pretreatment of A20-expressing
SMC with l-NAME (5 mM) did not affect its inhibitory
effect on IB degradation, as shown by WB (Fig. 5D,
n3). Similarly, pretreatment with l-NAME did not
alter the antiproliferative effect of A20 in SMC. A20-
expressing SMC did not significantly progress through
the cell cycle 24 h after addition of 10%FBS, whether
pretreated or not with l-NAME. A20-expressing SMC in
the SG2/M phases of the cell cycle increased from
12–18% prior to addition of FBS to 21.7 	 0.8% in
untreated SMC and 19.7 	 1% in l-NAME pretreated
SMC (PNS, n3 experiments performed in duplicate,
Fig. 5E). In contrast, the percentage of SMC in the
SG2/M phases of the cell cycle in NT and rAd.gal
transduced SMC doubled 24 h after addition of
10%FBS reaching 30.2 	 0.8% and 27.8 	 0.7% in
untreated SMC and 28 	 0.6% and 26 	 0.8% in
l-NAME pretreated SMC, respectively. There was even
a tendency to less cell proliferation in l-NAME pre-
treated SMC. These data strongly argue that the anti-
proliferative effect of A20 in SMC is NO independent.
Similarly, the antiapoptotic effect of A20 in EC was
not altered by NO blockade. The percentage of apo-
ptotic EC reached 44.5 	 1.6% and 46.5 	 2.4% in NT
and rAd.-gal transduced EC whereas it was half that
number in A20 expressing EC (28.1	2.7%) 9 h after
treatment with CHX/TNF (n4; P
0.01; Fig. 5E) (14).
The beneficial effect of A20 was not abrogated when EC
were pretreated with l-NAME for 4–6 h (the rate of
apoptosis was even lower, reaching 21.0	3.4%).
A20 expression inhibits neointima formation by
inhibiting SMC proliferation in vivo and supporting
regeneration of the endothelium
To test how these newly described functions of A20 in
SMC translate in vivo, we tested the effects of A20
Figure 5. TUNEL positive SMC are detected 48 h after cytokine treatment in A20-expressing SMC (A). Data shown are
representative of 3 independent experiments. Preincubation with l-NAME protects A20-expressing SMC from cytokine-
mediated apoptosis (FACS analysis of DNA content), Data shown is representative of 3 independent experiments (B). iNOS
mRNA is significantly higher in A20-expressing SMC compared to controls, 18 h after cytokine treatment as determined by
real-time PCR (C). Preincubation of SMC with l-NAME does not modify the inhibitory effect of A20 on IB degradation (D)
or its antiproliferative effect (E). Similarly, preincubation with l-NAME does not affect the antiapoptotic effect of A20 in EC
after CHX/TNF (E). Experiments shown are representative of 3 (SMC) and 4 (EC) independent experiments.
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expression on vascular remodeling after balloon angio-
plasty injury to rat carotid arteries. We injured left
common carotid arteries of adult male Sprague Dawley
rats and treated the vessels with normal saline, rAd.A20
or control rAd.-gal as detailed in the methods. We
found that 5  108 pfu achieved high levels of expres-
sion of the transgene in 30–40% of medial SMC at day
3 with a decrease by day 14, without any toxicity (Fig.
6B). We confirmed vascular A20 expression by RT-PCR
that showed expression of the human A20 transgene in
rAd.A20 transduced vessels while low levels of endoge-
nous rat A20 were detected in NT and rAd.-gal
transduced carotids (Fig. 6B). Endogenous A20 was not
detected in vessels overexpressing the human A20
transgene, consistent with the fact that A20 expression
is NF-B dependent, hence inhibited by the A20 trans-
gene (26). We observed significant neointimal hyper-
plasia in NT and rAd.-gal transduced carotids with
intima/media (I/M) ratios reaching 0.79 	 0.15 (n6;
nrefers to the number of animals/group) and 0.84 	
0.13 (n6), respectively. A20 expression significantly
inhibited neointima formation with an I/M ratio of
0.30 	 0.04 (n7; P0.022 vs. NT and P0.001 vs.
rAd.-gal) (Fig. 6A). This protective effect was main-
tained up to 28 days with I/M ratios of 0.79 	 0.11
(n6) and 0.70 	 0.17 (n6) in NT and rAd.-gal
transduced arteries while that of A20 expressing arter-
ies remained at 0.31 	 0.09 (n8; P0.004 vs. NT and
P0.044 vs. rAd.-gal; Fig. 6A).
Consistent with the antiproliferative function of A20
in SMC, in vitro, KI67 was significantly diminished in
A20 expressing vessels. (Fig. 6C). The number of KI67
positive cells was 91.2 	 22.0 per section (n3; “n”
refers to the number of vessels; 2 or more sections were
analyzed per vessel) in rAd.-gal transduced vessels
compared to 13.5 	 7.2 (n3; P0.03) in A20 express-
ing vessels. KI67 immunoreactivity was detected in both
medial and neointimal SMC in rAd.-gal transduced
carotids whereas its expression was limited to the few
neointimal SMC present in A20 expressing carotids. No
KI67 was detected in control noninjured vessels. We
used CD31 immunoreactivity, a specific marker of EC,
to probe for re-endothelialization of the injured ca-
rotids. Injured vessels did not express luminal CD31 3
days postinjury, confirming appropriate de-endotheli-
alization of all vessels. At 7 days postinjury, we detected
CD31 positive cells on 16.5	 5.5% (n4) of the lumen
in rAd.-gal transduced vessels in contrast to 57.0 	
9.7% (n3; P0.0008) in rAd.A20 transduced vessels
(Fig. 6C). Low levels of SMC apoptosis were detected by
TUNEL 3 and 7 days following balloon angioplasty and
were comparable in NT, rAd.A20, and rAd.gal trans-
duced vessels despite higher levels of iNOS mRNA in
A20-expressing SMC, as seen in vitro (Fig. 6B, C). This
later result indicates that the proapoptotic effect of A20
demonstrated in SMC cultures was either not relevant
in vivo when the A20 transgene was expressed in medial
SMC or that apoptotic SMC were rapidly cleared.
Figure 6. Evaluation of I/M ratio on H&E-stained rat carotid
arteries sections 14 and 28 days after balloon angioplasty dem-
onstrates significant neointimal lesions in NT and rAd.-gal
transduced vessels that are significantly inhibited in A20 express-
ing vessels. Arrows define the neointima (A). Transgene expres-
sion is confirmed by X-gal staining (100; inset 400) and
semiquantitative RT-PCR of -gal and A20 transduced vessels.
INOS mRNA, evaluated by semiquantitative RT-PCR is also
shown (B). Immunohistochemistry analysis of carotid arteries
sections 7 days after balloon injury demonstrates less KI67
staining (dark purple spots) in A20 expressing vessels compared
to rAd.-gal transduced vessels (C). Absence of CD31 immuno-
staining 3 days postinjury confirms equal de-endothelialization
in rAd.A20 and rAd.-gal transduced vessel with recovery of
CD31 luminal staining (rust color) 7 days after angioplasty in
A20 as opposed to -gal expressing vessels (C). No or little
apoptosis is detected by TUNEL at days 3 and 7 following
balloon injury. Few positive (blue) apoptotic cells are detected
in the adventitia. Uninjured vessels were used as control (C).
Representative sections are shown (100 and 400).
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The proapoptotic function of A20 appears restricted,
in vivo, to neointimal SMC and accounts for
regression of established neointimal hyperplasia
We next evaluated the impact of A20 expression in
neointimal SMC on already established neointimal
lesions. We injured the left common carotid artery and
allowed neointimal hyperplasia to develop for 28 days.
The I/M ratio at day 28 was at 0.91 	 0.1 (n6).
Injured vessels were then revisited and infused with
either normal saline or 5  108 pfu of rAd.A20 or
rAd.-gal. Rats were killed 14 days later and injured
carotids retrieved for morphometry and immunohisto-
chemistry analysis. The I/M ratio at day 28  14 in
saline and rAd.-gal transduced carotids reached
1.06 	 0.10 (n8) and 1.04 	 0.16 (n6), respectively,
and was not different from the I/M ratio measured
prior to gene transfer. In sharp contrast, injured ca-
rotids expressing A20 showed a remarkable reduction
of their I/M ratio to 0.49	 0.06 (n7; P0.0003 vs. NT
and P0.008 vs. rAd.-gal; Fig. 7A). Expression of the
transgene started rapidly, was optimal 3 to 5 days after
gene transfer and was detected to a depth of 3–4 cells
within the neointima as demonstrated by X-gal staining.
Expression of A20 was confirmed by semiquantitative
RT-PCR (Fig. 7B). We then evaluated by immunohisto-
chemistry the rate of proliferation (KI67) and apoptosis
(TUNEL) in vessels prior to gene transfer and at 28 
1, 28  3, 28  5 and 28  7 days after gene transfer.
Increased proliferation of neointimal SMC was de-
tected in NT and rAd.-gal transduced SMC at day 28
1, as depicted by increased KI67 immunostaining in the
first layers of the neointima, indicating that mere
re-exposure and saline infusion of neointimal lesions
led to some SMC injury. In contrast, no KI67 immuno-
reactivity was detected in A20-expressing SMC confirm-
ing that the potent antiproliferative effect demon-
strated in medial SMC equally applied, in vivo, to
neointimal SMC (Fig. 7C, n3). No significant apopto-
sis was detected at day 28 (Control) nor at day 28  1
in any of the groups studied. Apoptosis was however
drastically increased in neointimal SMC of rAd.A20
transduced vessels at days 28  3 and 28  5 reaching
55.7 	 4.3 apoptotic cells/section (n4). In contrast,
the number of apoptotic cells/section was much lower
reaching 11.2 	 1.6 and 9.1 	 3.5, in NT and rAd.-gal
transduced carotids, respectively (P0.0001 vs. NT and
P
0.0001 A20 rAd.-gal; n3; Fig. 7C). Sequential
analysis of A20 expressing carotids at days 28  1, 28 
3, 28  5 and 28  7 showed that neointimal SMC
apoptosis peaked at 28  3 and was no longer detected
by 28  7, at which point most of the neointima had
regressed (n3–4, Fig. 7D). This data clearly demon-
strates that the novel proapoptotic function of A20 does
indeed translate in vivo, but appears restricted to neo-
intimal SMC. SMC of the medial/contractile pheno-
type are not susceptible to A20-mediated apoptosis.
Correlating with our in vitro data implicating NO and
iNOS in A20-mediated SMC apoptosis; expression of
iNOS was increased in A20 expressing carotids and
Figure 7. Evaluation of I/M ratio on H&E-stained rat carotid
arteries sections at 28 and 28  14 days after balloon angioplasty
demonstrates regression of neointima in rAd.A20 transduced ves-
sels compared to NT and rAd.-gal transduced vessels. Arrows
define the neointima. (400) A) Expression of the transgenes
within the neointima is confirmed at day 28  3 by X-gal staining
(-gal) and semiquantitative RT-PCR (A20). A20 infected vessels
show also higher iNOS mRNA levels relative to NT and rAd.-gal
transduced vessels (semiquantitative RT-PCR) (B). Immunohisto-
chemistry performed at day 28  1 shows increased KI67 positive
cells (purple dots) in NT and rAd.-gal transduced vessels while no
KI67 immunostaining is detected in A20 expressing vessels (C).
Moderate iNOS immunoreactivity is detected in the first layers of
the neointima of NT and rAd.-gal transduced vessels contrasting
with significant iNOS immunostaining in rAd.A20 transduced
vessels at day 28 1 (C). Endothelial cell integrity is maintained in
NT and rAd.A20 transduced vessels as determined by CD31 con-
trasting with a significant loss of CD31 staining in rAd.-gal trans-
duced vessels at day 28 1 (C). Increased TUNELpositive cells are
detected at day 28  3 within the neointima of A20 expressing
vessels compared to NT and rAd.-gal transduced vessels (C).
Sequential analysis of neointimal SMC apoptosis in rAd.transduced
vessels, using TUNEL staining, demonstrates no apoptosis at 28
1 days that drastically increases at day 28  3 and is no longer
detected by day 28  7 (D). Sections of vessels retrieved 28 days
after balloon angioplasty injury were used as controls. Representa-
tive sections are shown (100 and 400).
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correlated with increased iNOS mRNA as detected by
semiquantitative RT-PCR (Fig. 7B, C). iNOS immuno-
reactivity scored at 1.8 	 0.06 in the first few layers of
the neointima of rAd.A20 expressing vessels at day 28
1, antedating the increase in apoptosis. In contrast,
iNOS immunoreactivity was significantly lower in NT
and rAd.-gal transduced vessels with scores reaching
1.2 	 0.1 in both groups (P0.004; n3; Fig. 7C).
NT vessels and vessels transduced with rAd.A20 dis-
played no significant EC loss at day 28  1 with CD31
positive luminal staining detected in 98.7 	 1.2% and
89.1 	 4.1%, respectively (n4). In contrast, CD31
luminal staining was decreased to 23.2 	 0.7% in
rAd.-gal infected vessels, presumably as a consequence
of adenoviral toxicity (P0.0004 vs. NT and P0.004
vs. rAd.A20; n4; Fig. 7C).
DISCUSSION
Increased SMC proliferation and acquisition of a proin-
flammatory phenotype are central features associated
with the development of neointimal lesions. We used
the balloon injury model to study whether inhibition of
multiple proinflammatory mediators by targeting a
central component of the proatherogenic signaling
cascades in SMC, namely NF-B, might curb neointima
formation. NF-B is required for the activation and
proliferation of SMC in vitro and for the formation of
atherosclerotic plaques in vivo (17). We have previously
demonstrated that A20 is a potent inhibitor of NF-B
including in EC (12, 13). In this study, we questioned
whether A20 retains this function in SMC.
We demonstrate that expression of A20 in SMC
inhibits NF-B activation upstream of IB degrada-
tion. This results in subsequent inhibition of NF-B-
dependent, proinflammatory, proatherogenic proteins
such as MCP-1 and ICAM-1. The incidence and severity
of vascular plaques in the atherosclerosis-prone, ApoE-
deficient mice are decreased when MCP-1 is blocked
and in ICAM-1 deficient mice (27, 28). Demonstration
of this potent anti-inflammatory function of A20 in
SMC qualifies its therapeutic potential for the preven-
tion of neointima formation (29).
Moreover, overexpression of A20 in SMC inhibits
their progression through the cell cycle by up-regulat-
ing the expression of the CDKI, p21waf1 as well as its
transcription activator, p53 before addition of FBS as
well as leading to a paradoxical increase of CDKI
p27kip1 levels after addition of FBS, enhancing the
“brakes” on cell cycle progression. The mechanism(s)
by which A20 leads to increased p53/p21waf1 and
p27kip1 expression remains to be determined. We have
recently demonstrated that p27kip1 is a target gene for
the Forkhead transcription factors belonging to the
FoxO subfamily and can be modulated to inhibit SMC
proliferation and neointimal hyperplasia (30). An ef-
fect of A20 on Forkhead transcription factors resulting
in the up-regulation of p27kip1 is being investigated.
Alternatively, p53 and CDKI p21waf1 and p27kip1 may be
the target of the ubiquitin-editing functions of A20,
possibly leading to their decreased degradation in the
proteasome (31). This would be consistent with the
described regulation of p53 and p21waf1 protein levels
by ubiquitination (32, 33). This hypothesis is being
investigated. However, the fact that SMC overexpress-
ing IB demonstrate an identical pattern of increased
p27kip1 and p53/p21waf1 and a comparable decrease in
FBS driven SMC proliferation, suggests that A20-medi-
ated inhibition of SMC proliferation could also result
from blockade of NF-B, considered an essential medi-
ator of SMC proliferation (17).
From a therapeutic standpoint, these results indicate
that by combining anti-inflammatory and antiprolifera-
tive functions, A20 fulfills two criteria required for the
prevention of neointima formation. The A20-mediated
benefit is remarkably sustained for more than 28 days
despite limited expression of the transgene, indicating
that the process of vascular remodeling is determined
very early after acute injury.
Expression of A20 in medial SMC after balloon
angioplasty led to accelerated re-endothelialization of
the injured vessels occurring 1 wk prior to that achieved
in rAd.-gal treated vessels. This effect may reflect
decreased inflammation in A20 expressing vessels facil-
itating healing processes including proliferation of
neighboring EC or seeding and differentiation of cir-
culating progenitor EC at the site of injury (34). It may
also be the result of the well-described proangiogenic
effect of NO, produced by A20 transduced SMC (35).
Alternatively, quicker re-endothelialization in A20 ex-
pressing vessels may relate to a novel pro-proliferative
function of A20 in EC that could have been transduced
at the edge of the lesion. Regardless of mechanisms,
limited EC loss and accelerated re-endothelialization
adds to the beneficial effect of A20 on vascular healing
(36). Indeed, seeding of injured vessels with EC or
fibroblasts after balloon angioplasty provides a “dress-
ing” that limits entry of circulating monocytes and T
cells hence decreasing inflammation and subsequent
neointimal hyperplasia (37).
In addition to increased SMC proliferation, deregu-
lated SMC apoptosis is a key contributor to neointimal
lesions (3, 38, 39). Restenosis following balloon angio-
plasty in humans is associated with decreased apoptosis
of neointimal SMC reflecting failure of apoptotic path-
ways to mediate neointimal regression (40, 41). Pro-
moting apoptosis of neointimal SMC is a logical thera-
peutic avenue to achieve regression of neointima. Our
data demonstrates that overexpression of A20, an
antiapoptotic protein in EC and other cell types, unex-
pectedly sensitizes SMC, in vitro, to apoptosis triggered
by two key proinflammatory mediators associated with a
proatherogenic environment: cytokines and Fas/FasL
cognate interactions (42, 43). The proapoptotic func-
tion of A20 in SMC is twice higher than that achieved in
IB-transduced SMC. In addition, coexpression of the
NF-B-dependent, antiapoptotic bcl protein A1 (whose
expression is equally blunted by IB and A20 overex-
pression) rescues IB but not A20-expressing SMC
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from apoptosis (21). Together, these data argue that
this novel proapoptotic effect of A20 is independent
from NF-B inhibition.
Rather, A20 promotes SMC apoptosis through a
NO-dependent mechanism. Blockade of NO produc-
tion reverts the sensitizing effect of A20 on cytokine-
mediated apoptosis. A20-mediated enhancement of
NO production has not been previously described and
did not manifest in the antiproliferative functions of
A20 in SMC nor in its antiapoptotic function in EC,
pointing to refined cell type specificity of A20 func-
tions. NO may promote SMC apoptosis through several
mechanisms including up-regulation of the death re-
ceptor Fas, activation of matrix metalloproteinases,
inhibition of NF-B and its dependent prosurvival
genes, peroxynitrite anion-mediated disruption of mi-
tochondrial integrity and direct damaging effect on
DNA (41, 44–46). Our data argues that direct DNA
damage is likely to be the dominant molecular target
for A20/NO-mediated apoptosis in our system.
In vivo, the proapoptotic function of A20 in SMC
does not manifest when A20 is expressed in medial
SMC immediately after balloon angioplasty. In contrast,
A20 expression in the first few SMC layers of established
neointimal lesions translates into a dramatic increase of
neointimal SMC apoptosis 3–5 days after gene transfer
leading to regression of neointimal hyperplasia. Ante-
dating apoptosis, iNOS immunoreactivity and mRNA
levels increase in A20 expressing neointimal SMC con-
sistent with in vitro evidence demonstrating the involve-
ment of NO in causing SMC apoptosis. iNOS is part of
the SMC response to injury and is likely a major
contributor to increased NO generation in A20-ex-
pressing SMC (47). We demonstrate a 2-fold increase in
iNOS mRNA levels in cytokine-stimulated A20-express-
ing SMC. Induction of iNOS at sites of inflammatory
coronary lesions or after injury to rat carotids or pig
iliac arteries inhibits neointimal hyperplasia (48). Con-
versely, blockade of iNOS by the NOS inhibitor l-
nitroarginine (L-NA) increases neointimal thickening
in young rats subjected to balloon angioplasty (49). To
clarify the contribution of iNOS in the atheroprotective
effects of A20, experiments are planned to treat L-NA
rats with A20 engineered carotids, subjected to balloon
angioplasty. The molecular mechanisms governing
A20-mediated up-regulation of iNOS mRNA are un-
known and quite unexpected. Indeed, inhibition of
NF-B in other cell types such as -cells blocks the
transcription of iNOS after stimulation with cytokines
(50). This could relate to increased iNOS mRNA sta-
bility and/or transcription by A20. The impact of A20
on the numerous transcription factors as well as regu-
latory processes, such as hypermethylation, that are
involved in regulating iNOS promoter activity will be
analyzed in a follow-up study (51, 52). The proapo-
ptotic function of A20 appears restricted in vivo to
neointimal SMC, which argues for an additional con-
centration of refined cell type-specific function(s) for
A20. These findings are consistent with studies using
antisense Bcl-xL oligos whereby medial vascular SMC
absorb antisense Bcl-xL oligos with a similar efficiency
as neointimal SMC, yet do not undergo apoptosis (7).
Collectively, these data stress the greater resistance to
apoptosis of medial SMC compared to neointimal SMC,
possibly an ultimate defense mechanism to maintain
vascular integrity.
In summary, we demonstrate that A20 is part of the
protective response of SMC to injury and significantly
contributes to vascular remodeling. It is expressed in
SMC response to inflammatory stimuli to control in-
flammatory and proliferative responses and sensitize
neointimal SMC to apoptosis. This later and unex-
pected function of A20 adds a therapeutic dimension to
its preventive effect against neointimal hyperplasia.
Our working model comprises two levels of A20 based
control of neointimal lesions. First, expression of A20
in medial SMC prevents neointima formation by shut-
ting down inflammatory and proliferative responses of
SMC via inhibition of NF-B and increased expression
of the CDKI p21waf1 and p27kip1. Second, SMC that
evade this first control and form a neointima are
sensitized by A20 to apoptosis via a NO-dependent
mechanism, which promotes regression of established
neointimal lesions (Fig. 8). We propose that A20
based therapies hold strong promise for the prevention
and cure of vascular neointimal disease including
in-stent restenosis, atherosclerosis and transplant
arteriosclerosis.
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Figure 8. A20 affords two levels of atheroprotective control.
First, expression of A20 in medial SMC prevents neointima
formation by shutting down inflammatory and proliferative
responses of SMC. Second, SMC that evade this first control
and localize to the neointima are sensitized by A20 to
apoptosis via a NO-dependent mechanism, hence leading to
regression of neointima.
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